IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 253 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,289,956 | -90.2% | 503,287 | -84.8% | 0.00% | -91.7% |
| Q2 2023 | $23,316,340 | +312.7% | 3,311,980 | +258.2% | 0.01% | +300.0% |
| Q1 2023 | $5,649,611 | +16.9% | 924,650 | +22.3% | 0.00% | 0.0% |
| Q4 2022 | $4,830,795 | -32.8% | 755,993 | +0.8% | 0.00% | -25.0% |
| Q3 2022 | $7,187,000 | -8.9% | 750,196 | +5.0% | 0.00% | 0.0% |
| Q2 2022 | $7,890,000 | +257.2% | 714,740 | +438.6% | 0.00% | +300.0% |
| Q1 2022 | $2,209,000 | +35.9% | 132,692 | +55.8% | 0.00% | 0.0% |
| Q4 2021 | $1,626,000 | -39.3% | 85,190 | -21.6% | 0.00% | 0.0% |
| Q3 2021 | $2,680,000 | +1325.5% | 108,677 | +1408.6% | 0.00% | – |
| Q2 2021 | $188,000 | -99.9% | 7,204 | -99.8% | 0.00% | -100.0% |
| Q1 2021 | $139,883,000 | +4827.2% | 4,418,284 | +7122.3% | 0.08% | +3650.0% |
| Q4 2020 | $2,839,000 | +40.4% | 61,176 | -0.4% | 0.00% | +100.0% |
| Q3 2020 | $2,022,000 | -11.5% | 61,428 | -26.2% | 0.00% | -50.0% |
| Q2 2020 | $2,284,000 | -72.4% | 83,202 | -69.9% | 0.00% | -71.4% |
| Q1 2020 | $8,270,000 | +20.3% | 276,257 | +11.2% | 0.01% | +75.0% |
| Q4 2019 | $6,872,000 | +36.5% | 248,322 | -10.3% | 0.00% | +33.3% |
| Q3 2019 | $5,036,000 | +187.8% | 276,745 | +287.2% | 0.00% | +200.0% |
| Q2 2019 | $1,750,000 | +161.2% | 71,466 | +1.1% | 0.00% | – |
| Q1 2019 | $670,000 | +2.9% | 70,680 | -4.1% | 0.00% | – |
| Q4 2018 | $651,000 | -89.6% | 73,694 | -86.8% | 0.00% | -100.0% |
| Q3 2018 | $6,263,000 | +18.6% | 556,848 | +34.9% | 0.00% | 0.0% |
| Q2 2018 | $5,282,000 | +94.5% | 412,736 | +156.7% | 0.00% | +100.0% |
| Q1 2018 | $2,716,000 | +141.9% | 160,807 | +14.4% | 0.00% | 0.0% |
| Q4 2017 | $1,123,000 | +6.0% | 140,536 | +2.6% | 0.00% | 0.0% |
| Q3 2017 | $1,059,000 | +132.2% | 136,909 | +120.5% | 0.00% | – |
| Q2 2017 | $456,000 | – | 62,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |